source
- Arrowhead’s siRNA shows strong tau reduction in early human study, outpacing other BBB platformsArrowhead Pharmaceuticals reported that its investigational siRNA candidate ARO-MAPT produced notable reductions in cerebrospinal fluid tau in a Phase 1/2a trial of healthy volunteers. Doses of 2.…
- Experts call for dedicated regulatory framework for clinical AI models, UK MHRA unveils AI-focused strategyFormer FDA commissioner Scott Gottlieb, now at the American Enterprise Institute, wrote an opinion piece urging Congress to create a specific regulatory framework for artificial intelligence models…raps · 6d agoRegulatoryPositive